How much funding has Day One Biopharmaceuticals raised?

Day One Biopharmaceuticals has raised $190.0M in total funding, most recently a series b round.

Who are Day One Biopharmaceuticals's investors?

Day One Biopharmaceuticals's investors include RA Capital Management, Canaan Partners, Fairmount Funds, Braidwell LP, Deerfield Management, Wellington Management.

When was Day One Biopharmaceuticals founded?

Day One Biopharmaceuticals was founded in 2018.

Where is Day One Biopharmaceuticals headquartered?

Day One Biopharmaceuticals is headquartered in Brisbane, California, United States.

What industry is Day One Biopharmaceuticals in?

Day One Biopharmaceuticals operates in Biotech, Healthcare.

How many employees does Day One Biopharmaceuticals have?

Day One Biopharmaceuticals has 51-200 employees.

Day One Biopharmaceuticals

IPO

Targeted Therapies for Children and Adults

Public · Brisbane, United States · Founded 2018 · $190.0M raised

Biotech

Healthcare

Headquarters: Brisbane, California
Employees: 51–200
Founded: 2018
Business Model: B2B
Website: dayonebio.com

Total Funding: $190.0M
Last Round: $130.0M Series BFeb 2021
Rounds: 2
Type: Public

About

Day One Biopharmaceuticals is a commercial-stage oncology company focused on developing and commercializing targeted therapies for patients with cancer, beginning with pediatric cancers. The company's lead product, tovorafenib (OJEMDA), is the first FDA-approved therapy for pediatric low-grade glioma (pLGG) and is being explored in additional tumor types driven by BRAF alterations.

Summary

Day One Biopharmaceuticals is a Biotech company based in Brisbane, United States, founded in 2018. It has raised $190.0M in total across 2 rounds, most recently a $130.0M Series B round in Feb 2021. Investors include RA Capital Management, Canaan Partners and Fairmount Funds.

LinkedIn X (Twitter)